<DOC>
	<DOC>NCT02543827</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of a biological vaccine (MV140) in women with Recurrent Urinary Tract Infections (RUTI) compared with a placebo group.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of MV140</brief_title>
	<detailed_description>Double blind parallel placebo controlled study. The subjects will receive medication during three or six months and will be followed up during another twelve months.</detailed_description>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<criteria>Gave written informed consent. Women Aged between 18 and 75 years. They must be able to meet the dosing regimen. Individuals who have had at least 3 episodes of cystitis in the past 12 months. Subject that does not have responded to health and hygiene measures and/or suppressive treatments and/or postcoital prophylaxis. Not have granted the informed written consent. Not included in the established age range. Not to offer cooperation I have serious psychiatric disorders. Present pathological postvoiding residue. Submit moderadagrave incontinence. Present genital tumors. Suffering from urinary tract tumors. Submit lithiasis. Present alterations in the immune system.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Recurrent Urinary Tract Infections (RUTI)</keyword>
	<keyword>Female Urogenital Diseases and Pregnancy Complications</keyword>
</DOC>